Rocket Pharmaceuticals, Inc. Operating Cash Flow
Rocket Pharmaceuticals, Inc. (RCKT) reported Operating Cash Flow of -$85.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$39.61M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$45.39M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$34.84M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$50.42M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$190.01M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$209.72M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$194.92M.
- Rocket Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$178.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$85.01M 10-Q · filed 2026-08-10 | -$119.85M derived: sum of 3 quarters · filed 2026-08-10 | -$170.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$45.39M 10-Q · filed 2026-05-07 | -$80.23M derived: sum of 2 quarters · filed 2026-05-07 | -$130.65M derived: sum of 3 quarters · filed 2026-05-07 | -$179.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$34.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$85.26M derived: sum of 2 quarters · filed 2026-02-26 | -$134.22M derived: sum of 3 quarters · filed 2026-08-10 | -$190.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$50.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$99.38M derived: sum of 2 quarters · filed 2026-08-10 | -$155.17M 10-Q · filed 2025-11-06 | -$202.12M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$48.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$104.75M 10-Q · filed 2026-08-10 | -$151.70M derived: sum of 3 quarters · filed 2026-08-10 | -$203.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$55.79M 10-Q · filed 2026-05-07 | -$102.73M derived: sum of 2 quarters · filed 2026-05-07 | -$154.84M derived: sum of 3 quarters · filed 2026-05-07 | -$208.66M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$46.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$99.05M derived: sum of 2 quarters · filed 2026-02-26 | -$152.87M derived: sum of 3 quarters · filed 2026-02-26 | -$209.72M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$52.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$105.93M derived: sum of 2 quarters · filed 2025-11-06 | -$162.78M 10-Q · filed 2025-11-06 | -$192.12M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$53.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$110.68M 10-Q · filed 2025-08-07 | -$140.02M derived: sum of 3 quarters · filed 2025-08-07 | -$197.17M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$56.86M 10-Q · filed 2025-05-08 | -$86.19M derived: sum of 2 quarters · filed 2025-05-08 | -$143.34M derived: sum of 3 quarters · filed 2025-05-08 | -$194.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$29.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$86.49M derived: sum of 2 quarters · filed 2025-02-27 | -$137.36M derived: sum of 3 quarters · filed 2025-02-27 | -$194.92M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$57.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$108.02M derived: sum of 2 quarters · filed 2024-11-07 | -$165.58M 10-Q · filed 2024-11-07 | -$221.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$50.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$108.43M 10-Q · filed 2024-08-06 | -$164.45M derived: sum of 3 quarters · filed 2025-02-27 | -$208.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$57.56M 10-Q · filed 2024-05-07 | -$113.58M derived: sum of 2 quarters · filed 2025-02-27 | -$157.44M derived: sum of 3 quarters · filed 2025-02-27 | -$196.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$56.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$99.88M derived: sum of 2 quarters · filed 2025-02-27 | -$138.92M derived: sum of 3 quarters · filed 2025-02-27 | -$178.14M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$43.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$82.90M derived: sum of 2 quarters · filed 2023-11-07 | -$122.12M 10-Q · filed 2023-11-07 | -$153.06M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$39.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$78.26M 10-Q · filed 2023-08-09 | -$109.20M derived: sum of 3 quarters · filed 2024-02-27 | -$136.62M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$39.22M 10-Q · filed 2023-05-05 | -$70.16M derived: sum of 2 quarters · filed 2024-02-27 | -$97.58M derived: sum of 3 quarters · filed 2024-02-27 | -$136.10M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$30.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$58.35M derived: sum of 2 quarters · filed 2024-02-27 | -$96.88M derived: sum of 3 quarters · filed 2024-02-27 | -$121.16M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$27.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$65.94M derived: sum of 2 quarters · filed 2022-11-04 | -$90.22M 10-Q · filed 2022-11-04 | -$103.33M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$38.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$62.81M 10-Q · filed 2022-08-09 | -$75.92M derived: sum of 3 quarters · filed 2023-02-28 | -$93.17M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$24.28M 10-Q · filed 2022-05-06 | -$37.39M derived: sum of 2 quarters · filed 2023-02-28 | -$54.65M derived: sum of 3 quarters · filed 2023-02-28 | -$76.68M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$13.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$30.36M derived: sum of 2 quarters · filed 2023-02-28 | -$52.40M derived: sum of 3 quarters · filed 2023-02-28 | -$74.64M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$17.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$39.29M derived: sum of 2 quarters · filed 2021-11-05 | -$61.53M 10-Q · filed 2021-11-05 | -$81.26M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$22.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$44.28M 10-Q · filed 2021-08-09 | -$64.01M derived: sum of 3 quarters · filed 2022-02-28 | -$74.86M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$22.25M 10-Q · filed 2021-05-10 | -$41.98M derived: sum of 2 quarters · filed 2022-02-28 | -$52.83M derived: sum of 3 quarters · filed 2022-02-28 | -$70.93M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$19.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$30.58M derived: sum of 2 quarters · filed 2022-02-28 | -$48.69M derived: sum of 3 quarters · filed 2022-02-28 | -$64.66M 10-K · filed 2022-02-28 |
| 2019-09-30 | -$10.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$28.95M derived: sum of 2 quarters · filed 2020-11-06 | -$44.93M 10-Q · filed 2020-11-06 | -$65.74M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$18.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$34.08M 10-Q · filed 2020-08-05 | -$54.90M derived: sum of 3 quarters · filed 2021-03-01 | -$66.53M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$15.98M 10-Q · filed 2020-05-08 | -$36.79M derived: sum of 2 quarters · filed 2021-03-01 | -$48.43M derived: sum of 3 quarters · filed 2021-03-01 | -$58.16M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$20.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$32.45M derived: sum of 2 quarters · filed 2021-03-01 | -$42.19M derived: sum of 3 quarters · filed 2021-03-01 | -$53.79M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$11.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$21.37M derived: sum of 2 quarters · filed 2019-11-08 | -$32.97M 10-Q · filed 2019-11-08 | -$38.96M derived: sum of 4 quarters · filed 2019-11-08 |
| 2018-06-30 | -$9.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$21.34M 10-Q · filed 2019-08-08 | -$27.33M derived: sum of 3 quarters · filed 2019-08-08 | -$31.42M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | -$11.60M 10-Q · filed 2019-05-09 | -$17.59M derived: sum of 2 quarters · filed 2019-05-09 | -$21.68M derived: sum of 3 quarters · filed 2019-05-09 | -$23.84M derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | -$5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | -$10.08M derived: sum of 2 quarters · filed 2019-03-08 | -$12.24M derived: sum of 3 quarters · filed 2019-03-08 | -$15.96M 10-K · filed 2019-03-08 |
| 2017-09-30 | -$4.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$6.25M derived: sum of 2 quarters · filed 2018-11-09 | -$9.97M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | -$2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$5.88M 10-Q · filed 2018-08-14 | ||
| 2017-03-31 | -$3.72M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | -$5.50M 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |